Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

NCT00620113 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

287

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis Postmenopausal

Interventions

DRUG: Odanacatib
DIETARY_SUPPLEMENT: Vitamin D3
DIETARY_SUPPLEMENT: Calcium carbonate
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC